tiprankstipranks
ImmunoCellular Therapeutics (IMUC)
OTHER OTC:IMUC
US Market

ImmunoCellular Therapeutics (IMUC) Stock Price & Analysis

177 Followers

IMUC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.15 - $0.42
Previous Close$0.23
Volume38.12K
Average Volume (3M)2.76K
Market Cap
$31.02M
Enterprise Value$28.17M
Total Cash (Recent Filing)$2.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta-0.24
Aug 13, 2018
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,193,498
10 Day Avg. Volume4,264
30 Day Avg. Volume2,761
Standard Deviation0.32
R-Squared0.00536
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

1.26%0.00%0.00%98.74%
1.26%
Insiders
0.00% Other Institutional Investors
98.74% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

IMUC FAQ

What was ImmunoCellular Therapeutics’s price range in the past 12 months?
ImmunoCellular Therapeutics lowest stock price was $0.15 and its highest was $0.42 in the past 12 months.
    What is ImmunoCellular Therapeutics’s market cap?
    Currently, no data Available
    When is ImmunoCellular Therapeutics’s upcoming earnings report date?
    ImmunoCellular Therapeutics’s upcoming earnings report date is Aug 13, 2018 which is 2054 days ago.
      How were ImmunoCellular Therapeutics’s earnings last quarter?
      Currently, no data Available
      Is ImmunoCellular Therapeutics overvalued?
      According to Wall Street analysts ImmunoCellular Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does ImmunoCellular Therapeutics pay dividends?
        ImmunoCellular Therapeutics does not currently pay dividends.
        What is ImmunoCellular Therapeutics’s EPS estimate?
        ImmunoCellular Therapeutics’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does ImmunoCellular Therapeutics have?
        ImmunoCellular Therapeutics has 113,270,750 shares outstanding.
          What happened to ImmunoCellular Therapeutics’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of ImmunoCellular Therapeutics?
          Currently, no hedge funds are holding shares in IMUC
          ---

          ImmunoCellular Therapeutics Stock Smart Score

          Company Description

          ImmunoCellular Therapeutics

          ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Actinium Pharmaceuticals
          Cellectar Biosciences
          Cyclacel Pharmaceuticals
          Advaxis
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis